Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Ownership  |  Insiders

Bioventus Inc BVS

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.


NDAQ:BVS - Post by User

Bullboard Posts
Post by JGrabaron Nov 08, 2023 8:42am
95 Views
Post# 35723175

$BVS Shareholder Suit Survives Motion to Dismiss

$BVS Shareholder Suit Survives Motion to DismissOn 11/23, by order of the U.S. District Court for the Middle District of North Carolina, the Defendants’ motion to dismiss the second amended complaint was denied, and the Plaintiffs Exchange Act claims under § 10(b) and § 20(a) were allowed proceed. $BVS
https://grabarlaw.com/the-latest/bioventus-shareholder-investigation/
Bullboard Posts